While European biotechs have historically prided themselves on capital efficiency, this mindset is now seen as a potential flaw in a global race for innovation. The focus is shifting towards bolder financing to generate value-driving data quickly, as efficiency is meaningless if a competitor reaches the market first.

Unlike large pharma where novel projects compete with established, safer alternatives, biotech startups derive immense power from their singular focus. The "live or die" mentality on a single hard problem forces teams to innovate and persevere through setbacks, which is essential for pushing true scientific boundaries.

Small biotechs must avoid becoming too attached to their initial lead compounds. They should adopt a 'first pancake' mindset, recognizing the first attempt may need to be discarded. This requires a professional, decision-driving approach over an emotional, project-tracking one.

Uniquity Bio, a 35-person firm, runs three Phase 2 trials concurrently—a resource-intensive strategy. This is possible because substantial private funding (from Blackstone) allows them to focus on clinical advancement rather than constant fundraising, de-risking an aggressive, multi-pronged approach.

Voyager Therapeutics can't afford massive, long-term clinical trials. Instead, it selects programs where it can use tools like imaging and fluid biomarkers to quickly and efficiently confirm a drug is working as intended. This strategy allows for early de-risking before committing massive capital.

Rahul Aras learned from his first venture that combining a novel target, a new modality (gene therapy), and a unique delivery device created too many unknowns. At Iterion, he prioritized minimizing such variables to create a more manageable risk profile for investors and partners, focusing on a single core innovation.

While biotech cannot easily replicate tech's rapid iteration cycles due to high costs and long feedback loops, it can adopt the capital efficiency model of tech seed investing. The strategy is to kill flawed projects quickly and cheaply, ensuring that when you lose, you lose small.

For small biotechs, the playbook for success extends beyond scientific discovery. It requires creativity and innovation in the operational process itself—finding efficient paths through regulatory checkpoints, securing non-traditional funding, and leveraging external resources to advance development with limited capital.

Founders must balance scientific conviction with market feedback. Kulkarni shares that his team abandoned pursuing certain indications that, while scientifically sound, failed to gain investor traction. This shows the critical need to pivot based on market signals, not just internal belief, to ensure continued funding and support.